Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Sjögren's syndrome medical therapy
Introduction
Overview
Overview
Pharmacologic medical therapies for dry eyes, dry mouth, and other sicca symptom of Sjögren’s syndrome are pilocarpine, cevimeline and artificial tears.
Medical Therapy
Medical Therapy
- Pharmacologic medical therapies for dry eyes, dry mouth, and other sicca symptom of Sjögren’s syndrome include:[1][2][3][4]
- Preferred regimen (1): Pilocarpine 5 mg PO q8h
- Preferred regimen (2): Cevimeline 30 mg PO q8h
- Preferred regimen (3): Artificial tears as needed
- Pharmacologic medical therapies for organ-based disease and constitutional symptoms of Sjögren’s syndrome include:[5][6][7][8]
- Preferred regimen (1): Hydroxychloroquine 200 mg PO q24h
- Preferred regimen (2): Methotrexate 0.2 mg/kg weekly
- Preferred regimen (3): Leflunomide 20 mg/day
- Preferred regimen (4): Azathioprine 3 to 5 mg/kg once daily
- Preferred regimen (5): Sulfasalazine 30 mg PO q8h
- Preferred regimen (6): Cyclosporine 5 mg/kg/day
- Preferred regimen (7): Cyclophosphamide 50-100 mg/m²/day
- Preferred regimen (8): Rituximab 375 mg/m2 once weekly for 4 doses
References
References
- ↑ Wu AJ (November 2008). “Optimizing dry mouth treatment for individuals with Sjögren’s syndrome”. Rheum. Dis. Clin. North Am. 34 (4): 1001–10, x. doi:10.1016/j.rdc.2008.08.013. PMID 18984418.
- ↑ Thanou-Stavraki A, James JA (April 2008). “Primary Sjogren’s syndrome: current and prospective therapies”. Semin. Arthritis Rheum. 37 (5): 273–92. doi:10.1016/j.semarthrit.2007.06.002. PMID 17714766.
- ↑ Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG (May 2012). “Topical and systemic medications for the treatment of primary Sjögren’s syndrome”. Nat Rev Rheumatol. 8 (7): 399–411. doi:10.1038/nrrheum.2012.53. PMID 22549247.
- ↑ Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R (December 2011). “Interventions for the management of dry mouth: topical therapies”. Cochrane Database Syst Rev (12): CD008934. doi:10.1002/14651858.CD008934.pub2. PMID 22161442.
- ↑ Nobeyama Y, Matsuzaki H, Nakagawa H (May 2014). “Annular erythema of Sjögren’s syndrome treated successfully with low-dose cyclosporine”. J. Dermatol. 41 (5): 463–4. doi:10.1111/1346-8138.12475. PMID 24801928.
- ↑ Yokota K, Shichinohe R, Hayasaka T (July 2005). “Topical tacrolimus in the treatment of annular erythema associated with Sjögren’s syndrome”. Clin. Exp. Dermatol. 30 (4): 450–1. doi:10.1111/j.1365-2230.2005.01803.x. PMID 15953102.
- ↑ Ramos-Casals M, Anaya JM, García-Carrasco M, Rosas J, Bové A, Claver G, Diaz LA, Herrero C, Font J (March 2004). “Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients”. Medicine (Baltimore). 83 (2): 96–106. PMID 15028963.
- ↑ Shahin AA, El-Agha S, El-Azkalany GS (July 2014). “The effect of leflunomide on the eye dryness in secondary Sjögren’s syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients”. Clin. Rheumatol. 33 (7): 925–30. doi:10.1007/s10067-014-2548-8. PMID 24647977.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]